The discovery that the E4 allele of the apolipoprotein E (apoE) gene is a putative risk factor for Alzheimer disease (AD) in the general population has highlighted the role of genetic influences in this extremely common and disabling illness. It has long been recognized that another genetic abnormality, trisomy 21 (Down syndrome), is associated with early and severe development of AD neuropathological lesions. It remains a challenge, however, to understand how these facts relate to the pathological changes in the brains of AD patients. We used computerized image analysis to examine the size distribution of one of the characteristic neuropathological lesions in AD, deposits of AP3 peptide in senile plaques (SPs). Surprisingly, we find that a log-normal distribution fits the SP size distribution quite well, motivating a porous model of SP morphogenesis. We then analyzed SP size distribution curves in genotypically defined subgroups of AD patients. The data demonstrate that both apoE £4/AD and trisomy 21/AD lead to increased amyloid deposition, but by apparently different mechanisms. The size distribution curve is shifted toward larger plaques in trisomy 21/AD, probably reflecting increased AP production. In apoE £4/AD, the size distribution is unchanged but the number of SP is increased compared to apoE E3, suggesting increased probability of SP initiation. These results demonstrate that subgroups of AD patients defined on the basis of molecular characteristics have quantitatively different neuropathological phenotypes.
The recent revolution in the molecular biology of disease has led to the development of molecular epidemiology, in which a population of individuals with a disease is subdivided according to molecular characteristics. Although rare families with Alzheimer disease (AD) have been linked to mutations in the amyloid precursor protein (APP) on chromosome 21 (1) or to an unknown gene on chromosome 14 (2) , by far the most common genetic predisposition for AD is conferred by inheritance of the s4 allele of the apolipoprotein E (apoE) gene (s4, gene; E4, protein). The apoE s4 allele is overrepresented by -4-fold in AD compared to age-matched control populations (3) (4) (5) . Although the apoE -4 allele frequency in the general population is only 0.14 (6) , it is present in >50% of the patients with AD that present to AD clinics (3) (4) (5) . Another genetic predisposition to AD is trisomy 21, in which essentially all individuals who live to their fifth or sixth decade develop severe neuropathological changes typical of AD (7) . It is unknown how these genetic alterations are related to the fundamental pathological alterations of the disease, specifically the deposition of AP3 amyloid peptide as senile plaques
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(SPs). There is a need to define the phenotypic correlations of these subgroups to forge a link between molecular epidemiology and pathophysiology.
SPs consist primarily of fibrilar deposits of a 39-to 42-amino acid peptide, A,B, which is derived from the transmembrane domain and extracellular portion of APP. Normal metabolism of APP leads to multiple degradation fragments, including small amounts of soluble A,B, which is present in tissues, plasma, and cerebrospinal fluid (8, 9) . AP3 is partially hydrophobic and can self-aggregate into (3-pleated sheets (10, 11) .
Although the exact relationship between deposition of A,B and dementia remains uncertain (12) (13) (14) , clinical studies in trisomy 21/AD and in apoE e4/AD show that there is increased deposition of A,B in both instances (4, 15, 16) . We have now applied tools derived from the study of polymer formation (17) to study the morphogenesis of SPs, particularly with regard to possible genetic influences.
METHODS
Tissue from 40 AD (age 78.3 ± 9.4 years, mean ± SD) and 7 elderly demented trisomy 21 (age 60.8 ± 4.2 years) patients was studied. Tissue samples were obtained from the Massachusetts Alzheimer Disease Research Center brain bank. All patients had a clinical history of dementia confirmed to be AD by neuropathological examination of paraffin-embedded Bielschowski-stained sections according to the CERAD protocol (18) . The tissue used in this study was 50-,um sections of the temporal lobe that were immunostained with antibody 10D5 (19) , a monoclonal antibody directed against A,B. A Bioquant image analysis system was used to semiautomatically assess SP number and cross-sectional area (13) , from which the size distribution of plaques was calculated (Fig. 1) .
In brief, immunostaining was carried out by using a horseradish peroxidase-linked anti-mouse secondary antibody and diaminobenzidine as chromagen. Thus Af3 deposits are dark brown against a blank background. A region 780 ,um wide by the depth of the cortex was examined in the inferior bank of the superior temporal sulcus, 1 cm from the crown of the gyrus. Consecutive x 160 magnification images from the pial surface to the gray/white junction were obtained by using a DAGE MTI CCD72 camera and digitized via a TARGA board. The Bioquant image analysis software allows identification of objects based on thresholding of the optical density and, thus, automatically will identify the dark AP3 deposits.
Operator editing was used to remove artifacts and vesselassociated AP3 deposits and to separate touching structures (4, 13) .
Abbreviations: apoE, apolipoprotein E; AD, Alzheimer disease; SP, senile plaque; APP, amyloid precursor protein.
The superior temporal sulcus was chosen because it is consistently affected in AD and is characteristic of the degree of involvement of association cortices (20) . Moreover, the superior temporal sulcus is a high-order association cortex and is one of only three trimodal association areas in the brain (21 (4) . RESULTS Development of Theory and Analysis of SP Size Distribution. We have studied SP size distribution histograms P(V), where P(V) AVis the fraction of SPs with a volume in the range V to V + AV Consideration of analogous problems in statistical physics (22) and of the biological issues influencing SP growth until reaching a steady state (13) leads to the following three possible models for the rate of increase in volume V of SPs.
(i) dV/dt = k(t), where k(t) is a parameter that changes with time in a random fashion around a positive average value until plaque size reaches a steady state. In this case, the histogram P(V), giving the number of SPs of volume V, is a Gaussian.
(ii) dV/dt = k(t)S, where S is the external surface area. For spheres, S is proportional to r2, while volume V is proportional to r3; here r denotes the typical radius. Hence, one can rewrite the equation in terms of r as dr/dt = k(t). The solution of this equation produces a histogram that is Gaussian in the variable r.
(iii) dV/dt = k(t)V, i.e., the rate is proportional to the volume. In this case, the histogram P(V) is dramatically skewed to the right. However, if we change variables from V to x = log V, then dx/dt = k(t); the distribution is Gaussian in this new variable and is thus log-normal (22, 23) .
The distribution of the cross-sectional area A, P(A), rather than P(V) is plotted because A was directly measured. In accord with previous observations, we found that the profile of plaque sizes when plotted as a function ofA along a linear axis is far from being Gaussian but instead is skewed to the right (13, 24, 25) (Fig. 2a) . We have now found that the SP size distribution profile can be approximated by a log-normal distribution. Indeed, when the distribution is plotted as a function of log A, it has the shape of a Gaussian (Fig. 2b) . Note that for roughly spherical objects, a log-normal distribution of crosssections yields a similar distribution as the volumes. Thus our data support models that result in a log-normal distribution and are inconsistent with models that predict a Gaussian distribution.
In general, a Gaussian for the P(V) histogram is usually found when Vis proportional to the sum of several parameters, each of which has independent fluctuations about its mean. In contrast, a log-normal distribution for the histogram occurs when V is proportional to the product of several parameters (23, 26, 27) , each of which has independent fluctuations about its mean. We have considered alternative explanations of the log-normal size distribution. If, for example, the coefficient k(t) is proportional to the product of random variables, each with independent fluctuations about the mean, then the SP size distribution would also be log-normal. Indeed, if k(t) were different for different lamina Genotype was determined by a PCR-based assay of the apoE gene (4) . Thirty-seven of the original 40 samples were apoE s3/3 (n = 15), apoE s3/4 (n = 15), or apoE s4/4 (n = 7). There are significant differences in amyloid deposition among genotypes. Analysis of variance with post hoc Fisher protected least significant difference showed significant (P < 0.05) differences (i) between apoE s3/3 and apoE E4/4 for amyloid burden, (ii) between apoE E3/3 and apoE E4/4 and between apoE s3/4 and apoE s4/4 for SP number, and (iii) no difference in SP size. . A curve generated from a theoretical log-normal distribution with the same mean and variance is shown as shaded bars to illustrate how well this distribution fits the data. each lamina were Gaussian, then the overall distribution for all lamina could be log-normal. To rule out this possibility, we computed the distributions of plaques within an observation window of size 500 x 500 ,.m that we slide inside broad samples of a cortical traverse section of 3500 ,um long and -3000 ,um deep. For each position of the window, we measured the number of plaques within the window and the mean and standard deviation of the log-normal distributions. This method allows us to obtain 11 parallel profiles of the studied quantities. Each profile has 50 data points that correspond to different depths of cortex from 0 depth on the cortical surface to the maximal depth at the gray-white boundary. The distance between successive profiles is 300 ,pm. We found that the profiles are similar at all depths. These similarities suggest the presence of strips with a high density of plaques that are parallel to the cortical surface, e.g., in the laminae. The parameters of the log-normal distribution do not change systematically along the profiles, staying almost constant for all the positions of the observation window. This indicates that the process of plaque growth does not change for different cortical depths.
Influence of ApoE Genotype and Trisomy 21 on Amyloid Deposition. The observation that SP size is similar for all cases studied and fits the log-normal law allows quantitative comparison across different subgroups of AD patients defined by molecular characteristics. This is of particular relevance in two instances where increased amyloid deposition occurs, apoE e4/AD and trisomy 21 AD. Jarrett and Lansbury (28) We tested the first prediction by studying elderly trisomy 21 individuals with AD, where there is elevated deposition of AP presumably due to the triplication and overproduction of APP.
Comparison of >3000 SPs from 7 elderly demented trisomy 21/AD patients to >19,000 SPs from 40 AD patients showed increased amyloid deposition in trisomy 21/AD (P < 0.001) (Fig. lb) . The trisomy 21/AD curve is shifted to the right toward larger size (P < 0.001) (Fig. 3) . Note that the x axis is a logarithmic base-4 scale, so that a move to the right of 1 unit is a 4-fold increase. These results provide quantitative evidence consistent with the idea that increased A,B production is the cause of the increased amyloid deposition in trisomy 21 Inheritance of the apoE s4 allele is also associated with increased deposition of A,B (Fig. lc) (16) . Because apoE binds hydrophobic macromolecules such as low density lipoproteins and transports them to specific receptors for cellular uptake, it has been suggested that one role of apoE in the pathophysiology of AD is to act as a clearance mechanism for AP3 or AP3
aggregates (4) . This hypothesis is supported by the observations that apoE binds AP3 in vitro (29, 30) , and apoE (4, 31) clearing small A13 aggregates than apoE3, this would lead to an increased chance that an aggregate would reach a critical threshold size and lead to an increased SP number but not affect the size distribution. To test these two possibilities, we analyzed the size distribution data with the AD sample divided by apoE genotype. We found that the apoE s4 genotype is associated with increased numbers of SPs (Fig. lc) . Different apoE genotypes have essentially identical size distribution profiles (Fig. 4) . This result suggests that the likelihood of successful nidus formation is greater with apoE. We postulate that either apoE4 (compare to apoE3) enhances precipitation of AP as a pathological chaperone (31) (32, 33) . The interpretation that SPs are porous would also explain the puzzling observation that cut surfaces (rather than just the rim) of SPs immunostain for multiple SP-associated antigens, including apoE (4).
(ii) Our data demonstrate that subgroups of AD patients defined by molecular properties differ with regard to quantitative characteristics of a fundamental aspect of the pathology of the disease: deposition of Af3. Increased amyloid burden occurs in AD associated with both trisomy 21 and apoE s4, implying an increased rate of Af3 deposition in both circumstances. The results provide quantitative evidence that increased Af3 levels underlie deposition in trisomy 21. By analogy, the same may hold true for patients who inherit the Swedish APP mutation, which leads to overproduction of A,3 (34, 35) . The current results also suggest that the association of apoE s4 with increased A,B deposition may be due to increased initiation of SPs, perhaps related to increased stability or decreased clearance of A,B aggregates. Thus individuals who inherit both trisomy 21 and apoE s4 develop extraordinarily high amyloid burdens (15) . These observations fit with a formulation that the rate of A13 deposition is a reflection of the relative rates of AP3 synthesis, aggregation, and clearance.
Recent evidence suggesting that APP717 mutations lead to the production of a greater percentage of A13-(1-42), which has a greater tendency than AB3-(1-40) to aggregate (36) , also fits with this formulation. Thus, these data provide evidence favoring heterogeneity in the mechanisms of Af3 deposition in different molecularly defined subgroups of AD patients.
